Jian Qin (Michael) Yu, MD, FRCPC
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497
PET scans are scheduled through the referring physician's office. Call 215-728-3883/2656.
Chief, Nuclear Medicine
American Board of Nuclear Medicine;
The Royal College of Physicians and Surgeons of Canada, Fellow
Certification Board of Nuclear Cardiology;
Certified Clinical Densitometrist (CCD)
I joined the staff at Fox Chase Cancer Center in 2005 as Chief of Nuclear Medicine and PET service.
I chose the field of Nuclear Medicine and PET because I am interested in functional and molecular imaging. The nuclear medicine studies provide sensitive and early detection for many disease processes. It's gratifying when I can help cancer patients by staging (determining the extent of) and restaging their tumor correctly, monitoring their response to therapy and checking for recurrence (the cancer coming back).
I choose to practice at Fox Chase because of its emphasis on a team approach to patient care and for the opportunity to do research. I work closely with other cancer experts to provide the best care possible for our patients.
My clinical interests focus on the use of positron emission tomography (PET) for diagnostic and molecular imaging. I also take care of patients who receive radiotargeted and radioimmune therapy.
My research interests involve PET and targeted therapy in oncology. I am involved in several imaging trials with cooperative groups, such as the Radiation Therapy Oncology Group (RTOG), Gynecologic Oncology Group (GOG) and American College of Radiology Imaging Network (ACRIN). I also participate in several industry-sponsored national and international studies for drug development and evaluation.
In addition to my clinical and research duties at Fox Chase, I am an active member of the Center's Institutional Review Board (IRB) and the Radiation Safety Committee.
Beijing Medical University, Beijing, China, 1987
General Surgery, Beijing Medical University, Beijing, China;
Internal Medicine, MCP-Hahnemann University Hospital, Philadelphia, Pa;
Nuclear Medicine, MCP-Hahnemann University Hospital, Philadelphia, Pa.;
Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pa.
PET, Hospital of the University of Pennsylvania, Philadelphia, Pa.;
Pediatric Nuclear Medicine, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, Philadelphia, Pa.
The Royal College of Physicians and Surgeons of Canada;
Society of Nuclear Medicine;
The International Society for Clinical Densitometry;
American Society of Nuclear Cardiology;
American College of Radiology;
Radiological Society of North America
Dr. Yu on My NCBI
- Yu JQ, Zhuang HM, Xiu Y, Talati E, Alavi A. Demonstration of Increased FDG Activity
in Rosai-Dorfman Disease on Positron Emission Tomography. Clinical Nuclear Medicine 29 (3): 209-210 MAR 2004 (PMID: 15162996)
- Yu JQ, Kumar R, Xiu Y, Alavi A, and Zhuang HM. Diffuse FDG uptake in the lungs in
patient with aspiration pneumonia on Positron Emission Tomographic imaging. Clinical Nuclear Medicine 29 (9): 567-568 SEPT 2004 (PMID: 15311127)
- Yu JQ, Milestone BD, Parsons R, Doss M, Haas N: Findings of Intra-Mediastinal
Gossypiboma with F-18 FDG PET in a Melanoma Patient. Clinical Nuclear Medicine 33(5):344-345, May 2008 (PMID: 18431152)
- Doss M, Zhang JJ, Bélanger MJ, Stubbs JB, Hostetler EB, Alpaugh RK, Kolb H, Yu
JQ: Biodistribution and Radiation Dosimetry of the Hypoxia Marker 18F–HX4 in monkeys and humans determined from whole-body PET/CT, Nuclear Medicine Communications 31(12): 1016-24; [Epub 2010 Oct 13] (PMID: 20948452/NIHMSID#: 259162/PMCID: PMC3016990)
- Reddy S, Shaller CC, Doss M, Shchaveleva I, Yu JQ, Robinson MK: Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clinical Cancer Research, 2011 Mar.15; 17(6):1509-1520; [Epub 2010 Dec.21] (PMID: 21177408/PMCID: PMC3060271)
- Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Adams GP,
Robinson MK: Impact of Expression System on the Function of the C6.5db PET
Radiotracer, Tumor Biology, 2012; 33(3):617-27 [Epub 2012 March 1], PMID:
- Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig CJ, Yu JQ, Vallabhajosula S, Larson SM, Schoder H, English P, Neuberg DS, Martin P, Ely SA, Courtney R, Shaik N, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT and Shapiro GI: Selective CDK4/6 Inhibition with Tumor Responses by PD0332991 in Patients with Mantle Cell Lymphoma, Blood, 2012 119: 4597-4607 with editorial, [Epub 2012 March 1], PMID: 22383795
- Doss M, Kolb HC, Zhang JJ, Bélanger M, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh
RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ*: Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 in monkeys and humans determined from whole-body PET/CT, Journal of Nuclear Medicine 2012; 53:787-795 [Epub 2012 Apr 12], PMID: 22499613
- Divgi C, Uzzo R, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo J, Larson S, Bevan P, Russo P: PET/CT Identification of Clear Cell Renal Cell Carcinoma: Results of the REDECT Trial. Journal of Clinical Oncology, January 10, 2013: vol. 31, no. 2, 187-194. [Epub Dec. 3, 2012], PMID: 23213092
- Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R,
Galloway T, Ridge J: Extranodal extension of Metastatic Papillary Thyroid Carcinoma: Correlation with biochemical endpoints, nodal persistence and systemic disease progression. Thyroid, 23(9), 1099-1105 [Epub Feb. 19, 2013], PMID: 23421588/PMCID: PMC3770240